Special drug use Surveillance for EFIENT Tablets - Patient with ischemic cerebrovascular disease with a high risk of ischemic stroke -

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031220131

Enrollment

1200

Registered

2022-06-12

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic cerebrovascular disease (associated with large-artery atherosclerosis or small-vessel occlu

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who fulfilled the following criteria: (1) Patients with ischemic cerebrovascular disease associated with large-artery atherosclerosis or small-vessel occlusion (restricted to cases with a high risk of ischemic stroke*1), who were administered EFIENT for the first time *1: Patients with either hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease or a history of ischemic stroke before the last episode of attack (2) Patients who started administration of EFIENT tablet during the contract period (contract period based on the contract with each medical site) and until 30/June/2023 (3) Patients from whom written informed consent was obtained

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
-Incidence of bleeding events -Incidence of ischemic stroke events	—

Contacts

Public ContactGPSP Contact

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results